Skip to content

PressReach

SEARCH

Investing
Featured
Market
Biotech
Oil & Gas
Mining
Gaming
Tech
Crypto
More

Search

SEARCH FOR AN ARTICLE

Search

Investing
Featured
Market
Biotech
Oil & Gas
Mining
Gaming
Tech
Crypto
More

PressReach

HomeParkinson’s disease

Parkinson’s disease

Annovis Bio’s Phase III Dosing Begins for Parkinson’s Study

Annovis Bio’s Phase III Dosing Begins for Parkinson’s Study

August 25, 2022

LATEST NEWS

Investing News Intel’s Turnaround Gains Momentum
Investing News Volkswagen’s Earnings Reveal Market Trends
Investing News Dover’s Industrial Struggles
Investing News Honeywell’s Post-Spinoff Growth
Investing News Comcast Earnings Show Strength

PressReach

All logos, trade names and/or trademarks, artwork and associated imagery are trademarks and/or copyright material of their respective owners.

Advertisers
Privacy Policy
Terms of Use
DMCA Policy
Disclaimer
Contact Us

SUBSCRIBE

To get email updates from PressReach.

I want e-mail alerts, updates, and offers and agree to the PressReach privacy policy.

Market Jar Media Inc. © 2026